Novel Molecule

We are actively investing in advanced treatment platforms like Chimeric Antigen Receptor T (CAR-T) cell therapy, with efforts underway to build end-to-end capabilities in India supported by our licensing partners. Our wholly owned subsidiary, Aurigene Oncology Limited, is focused on discovering and advancing potentially best-in-class therapies for cancer and inflammatory diseases.\n\nWhile our own pipeline is in the early stages of development, we remain focused on its long-term potential to address unmet needs. In parallel, we are accelerating access to innovative products through partnerships, especially in underserved therapeutic areas and/or markets. These efforts include voluntary licensing agreements for breakthrough treatments such as Lenacapavir. Through these initiatives, we aim to make the promise of innovation a reality for patients who need it most.